Man Group
OMGA

Man Group’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Man Group’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,409
Closed -$114K – 1966
2022
Q4 		$93.7K Buy
+16,409
New +$92.1K ﹤0.01% 1916

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's OMGA Position: Q1 2023 in Review

Man Group sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2023, closing a stake of 16,409 shares — an estimated $114K sold.

Man Group first reported a position in OMGA in Q4 2022 and held it in 1 quarter. The position peaked at $93.7K in Q4 2022. 54 funds tracked by Wall St. Rank hold OMGA as of Q1 2023.

  • Man Group reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 16,409 Omega Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $114K.
  • Man Group first reported a position in Omega Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Man Group's Omega Therapeutics, Inc. Common Stock position peaked at $93.7K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.